投资建议:联影医疗是国产医疗影像设备制造龙头,拥有丰富产品线和先进产品性能，有望充分受益医疗 新基建及大型设备更新等政策，海外市场前景亦颇为广阔，公司长期发展动力丰沛。考虑到国内招采活 力仍有待进一步恢复，我们调整并预测公司2025-2027年归母净利润至18.60/24.24/31.41亿元，同比增长 47.41%/30.32%/29.57%，EPS分别为2.26/2.94/3.81元，当前股价对应2025-2027年PE55/42/33倍，维持"推 荐"评级。风险提示:海外拓展不及预期的风险、政策不确定的风险、招投标活力恢复不及预期的风险。 2024年:国内业务阶段性承压，海外拓展持续取得新突破。公司销售医学影像诊断设备及放射治疗设备 业务实现收入84.45亿元(-14.93%)，毛利率为47.05%(+0.87pct)，其中CTMR/MI/XR/RT产品分别实现销 售收入30.48131.92112.9915.8713.19亿元，同比-25.03%、-2.66%、-16.31%、22.80%、+18.05%;维修服务 业务实现收入13.56亿元(+26.809)。分地区来看，1)境内:实现收入76.64 ...

迈瑞医疗 20250624 摘要 2022 年 Q4 贴息贷款政策刺激招采后迅速回落，2024 年 9 月后招投标 趋势好转，预计 2025 年后行业有望底部反转，为股票交易提供关键时 间节点参考。 迈瑞医疗估值较强生、雅培、美敦力等全球医疗器械巨头更具竞争力， 是中国唯一市值超 200 亿美元的医疗器械公司，收入、利润及人均创收 表现突出。 迈瑞医疗通过近 20 年的收并购策略，横向拓展能力强，中国及全球业 务规模大，市占率有望进一步提高，未来增长潜力巨大。 受益于医疗新基建加速和发展中国家市场增长，以及 2009-2011 年 8,500 亿财政投入和 2022 年贴息贷款政策，迈瑞主营业务收入持续增 长。 迈瑞通过海外并购（如 Datascope 医护监控设备业务、海泰、德赛、 惠泰等）拓展原料及渠道，成功绑定拉动海外收入长期增长，国际化战 略成效显著。 Q&A 迈瑞医疗在当前的市场环境中有哪些主要优势？ 迈瑞医疗在当前市场环境中的主要优势包括以下几个方面： 迈瑞医疗相较于业绩稳定期的美股医疗器械巨头，仍处于高成长阶段， 营收和净利润增速位居全球前列，费用管控能力强，净利润稳居国际巨 头首位。 全球医疗 ...

· 医药生物行业 超配（维持） 触底反弹把握景气方向 医药生物行业 2025 年中期投资策略 2025 年 6 月 13 日 分析师：谢雄雄 SAC 执业证书编号： S0340523110002 电话：0769-22110925 邮箱： xiexiongxiong@dgzq.com.cn 医药生物（申万）指数走 势 资料来源：Wind，东莞证券研究所 相关报告 投资要点： ◼ 风险提示：行业竞争加剧，产品降价，产品安全质量风险，政策风 险，研发进度低于预期等。 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。请务必阅读末页声明。 投 资 策 略 行 业 研 究 证 券 研 究 报 告 ◼ 2025年上半年市场走势回顾。2025年1-5月份，SW医药生物行业指 数整体上涨6.61%，涨幅居申万一级行业第6位，跑赢同期沪深300 指数约9.02个百分点。SW医药生物行业多数细分板块均录得正收 益，其中化学制剂和原料药板块涨幅居前，分别上涨19.59%和 17.01%；疫苗和血液制品板块跌幅居前，分别下跌9.01%和 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is expected to see a turning point in its domestic business in 2025 due to the anticipated recovery in local special bonds and monthly bidding for various medical devices, despite short-term impacts from tight local finances and delays in regular tenders [1] - The international market is projected to grow significantly, driven by the company's continued penetration into high-end customer segments and balanced revenue distribution across major global regions, particularly in developing countries and Europe [1] - The company is expected to maintain steady long-term growth, supported by the global medical infrastructure wave and expansion into high-end markets [5] Business Segmentation and Highlights - **Life Information and Support Segment**: Revenue decreased by 11.1% in 2024, with minimally invasive surgery business growing over 30%. Internationally, this segment achieved double-digit growth [2] - **In Vitro Diagnostics Segment**: Revenue grew by 10.8% in 2024, surpassing the Life Information and Support segment for the first time. Internationally, this segment saw growth exceeding 30% [3] - **Medical Imaging Segment**: Revenue increased by 6.6% in 2024, with international business growing over 15%. The high-end ultrasound system Resona A20 generated over 400 million yuan in its first year [3] Profitability Analysis - The company's gross margin for 2024 was 63.1%, a decrease of 3.0 percentage points year-on-year, while the net profit margin was 32.0%, down 1.2 percentage points [4] - Operating cash flow for 2024 was 12.43 billion yuan, a year-on-year increase of 12.4%, representing 102.8% of net operating income [4] - Profitability is expected to improve slightly from 2025 to 2027, driven by an increase in high-end product sales and stable operating expense ratios [4] Financial Forecast and Valuation - The company is projected to maintain stable growth from 2025 to 2027, with expected revenues of 40.33 billion yuan in 2025, 45.76 billion yuan in 2026, and 52.50 billion yuan in 2027, reflecting growth rates of 9.82%, 13.46%, and 14.72% respectively [12] - The estimated earnings per share (EPS) for 2025 is 10.61 yuan, with a price-to-earnings (P/E) ratio of 21.86 [10][12]

投资要点： 盈利预测与投资建议 我们预计公司2025-2027 年收入分别为28/36/48 亿元，同比增长61%/32%/33% ， 归母净利润分别为 1.7/2.2/3.0 亿元， 同比增长156%/30%/35%。采用可比公司估值法，我们选取具有洁净室业务的圣晖集 成、至纯科技、柏诚股份、亚翔集成为可比公司，计算得出25 年平均PE 倍数为21 倍。我们认为，随着 公司基于已有医疗洁净室领域的案例经验及优势，主业稳固基本盘并稳健增长，依赖武汉高新区资源禀 赋外延拓宽半导体洁净室打开成长空间，业绩有望高速增长，首次覆盖给予"买入"评级。 风险提示 新业务拓展不及预期；医疗新基建落地速度不及预期；竞争格局恶化的风险。 头部医疗洁净室厂商，外延发力电子洁净大市场公司成立于2008 年，为头部洁净室系统集成化解决方 案服务商，参与火神山医院项目建设。公司业务范围由医疗扩大至实验室集成服务、电子洁净等多个领 域，构建第二增长曲线，现已服务过800 余家公立医院、高等院校、工业电子企业等客户。2025 年3 月，公司公告由"华康医疗"更名为"华康洁净"，24 年12 月发行7.5 亿元可转债支持新业务布局，构建半 ...

华福证券 医疗设备 2025 年 05 月 23 日 公 司 研 究 华康洁净（301235.SZ） 头部医疗洁净厂商，高景气电子洁净第二曲线 投资要点： 头部医疗洁净室厂商，外延发力电子洁净大市场 公 司 首 次 覆 盖 公司成立于 2008 年，为头部洁净室系统集成化解决方案服务商， 参与火神山医院项目建设。公司业务范围由医疗扩大至实验室集成服 务、电子洁净等多个领域，构建第二增长曲线，现已服务过 800 余家 公立医院、高等院校、工业电子企业等客户。2025 年 3 月，公司公告 由"华康医疗"更名为"华康洁净"，24 年 12 月发行 7.5 亿元可转债 支持新业务布局，构建半导体生态战略合作，4 月 24 日，九峰山实验 室、武汉光谷金融控股集团与武汉华康世纪洁净科技股份有限公司联 合宣布，三方拟共同组建"武汉光谷华峰运维技术有限公司"，背靠光 谷、生态共建、夯实未来成长空间。 主业医疗端在手订单充足，持续稳健 疫后医疗新基建加速，洁净手术室增量建设+存量改造，根据公司 可转债募投说明书数据，我国医疗净化系统市场规模每年约为 312.68 亿元。行业集中度较低，华康洁净于资质、人员、行业地位与项目经 ...

Investment Rating - The investment rating for the company is maintained at "Buy" with a target price of RMB 328.30 [7][8]. Core Views - The company reported a revenue of RMB 367.26 billion and a net profit attributable to the parent company of RMB 116.68 billion for 2024, reflecting a year-on-year growth of 5.1% and 0.7% respectively. The profit was below market expectations due to delays in domestic equipment upgrade policies [1]. - The company is expected to achieve steady growth in 2025, driven by the acceleration of domestic equipment upgrade policies and ongoing efforts in product promotion both domestically and internationally [1]. - The company’s three core business segments are projected to perform well in 2025: 1. IVD segment revenue reached RMB 137.65 billion in 2024, with a year-on-year increase of 10.8% and strong overseas growth [2]. 2. Medical imaging segment revenue was RMB 74.98 billion, up 6.6% year-on-year, supported by the launch of high-end products [2]. 3. Life information and support segment revenue was RMB 135.57 billion, down 11.1% year-on-year, but expected to rebound in 2025 due to improving domestic policies [2]. Summary by Sections Financial Performance - The company’s revenue for 1Q25 was RMB 82.37 billion, with a net profit of RMB 26.29 billion, showing a year-on-year decline of 12.1% and 16.8% respectively, but a quarter-on-quarter increase of 13.8% and 154.9% [1]. - The company’s revenue forecast for 2025 is RMB 40.545 billion, with a projected net profit of RMB 12.84 billion, reflecting a growth of 10.04% [6]. Market Expansion - The company’s overseas revenue reached RMB 164.34 billion in 2024, growing by 21.3%, with significant contributions from the Asia-Pacific and European regions [3]. - Domestic revenue was RMB 202.92 billion, down 5.1% year-on-year, but expected to improve in 2025 due to the release of medical infrastructure orders and enhanced competitiveness [3]. Profitability and Valuation - The EPS forecast for 2025 is adjusted to RMB 10.59, with a PE ratio of 31x for 2025, leading to a target price of RMB 328.30 [4]. - The company is recognized as a leading domestic medical device manufacturer with strong brand influence and a continuously improving global sales network [4].

证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20250401 | | 特定对象调研 分析师会议  | | | --- | --- | --- | | 投资者关系活 | 媒体采访  业绩说明会 | | | 动类别 | 新闻发布会 路演活动 | | | | 其他 | | | 地点 | 宝莱特公司会议室、价值在线（https://www.ir-online.cn/） | | | | 线上参与公司 2024 年度业绩网上说明会的全体投资者 | | | 上市公司接待 | 董事长兼总裁 燕金元先生 | | | 人员姓名 | 独立董事 杨振新先生 | | | | 保荐代表人 | | | | 财务总监 | | | | 董事会秘书兼副总裁 杨永兴先生 | | | | 问答交流环节： | | | | 1、请问贵公司本期财务报告中盈利表现如何？ | | | | | 年一季度）公司营业收入 | | | | 7.17%；归属 | | | 于上市公司股东的净利润 元，上年同期为 14,448,489.46 | 元， | | | 同比增长 | | | | 338,833 ...